Galectin Therapeutics Balance Sheet - Quarterly (NASDAQ:GALT)

Add to My Stocks
$6.05 $0.03 (0.5%) GALT stock closing price Sep 19, 2018 (Closing)

A thorough fundamental analysis involves using data from Galectin Therapeutics balance sheet, apart from other financial statements, to value the business. Financial strength can be guaged by performing Galectin Therapeutics stock analysis and by analyzing the balance sheet. Good quarterly results indicate a company's strong financial performance. Its important to check all financial statements including the balance sheet. Galectin Therapeutics had a long term debt of $- at the end of 2018 Q2. To understand the debt servicing capacity of the company, one needs to look at Galectin Therapeutics operating cash flow and Galectin Therapeutics revenue also. Galectin Therapeutics debt to equity ratio is .

View and download Galectin Therapeutics quarterly results to get the balance sheet details for the latest 40 quarters data.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Marketable Securities----------
Raw Materials----------
Work In Progress----------
Finished Goods----------
Notes Receivable----------
Other Current Assets----------
Total Current Assets
Property Plant & Equipment----------
Accumulated Depreciation----------
Net Property Plant & Equipment
Investment & Advances----------
Other Non-Current Assets----------
Deferred Charges----------
Deposits & Other Assets----------
Total Assets
Notes Payable----------
Accounts Payable-1.15M---1.34M---1.31M
Current Portion Long-Term Debt----------
Current Portion Capital Leases----------
Accrued Expenses1.15M1.13M2.29M4.17M3.04M3.01M2.8M3.43M2.63M1.93M
Income Taxes Payable----------
Other Current Liabilities----------
Total Current Liabilities
Deferred Taxes/Income----------
Convertible Debt----------
Long-Term Debt----------
Non-Current Capital Leases----------
Other Long-Term Liabilities----------
Total Liabilities
Minority Interest----------
Preferred Stock8.95M8.96M8.96M8.96M8.96M8.96M8.96M8.34M7.68M7.62M
Common Stock Net----------
Capital Surplus190.6M179.35M173.36M172.05M170.53M169.54M166.72M162.17M159.78M158.94M
Retained Earnings-189.82M-185.71M-181.16M-178.38M-173.71M-168.91M-163.7M-158.52M-152.88M-147.06M
Treasury Stock----------
Other Liabilities----------
Shareholders Equity9.78M2.64M1.19M2.67M5.81M9.63M12.01M12.02M14.61M19.53M
Total Liabilities & Shareholders Equity11.21M4.93M4.16M7.01M9.32M13.99M15.79M16.11M18.24M22.78M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Most investors just check the Galectin Therapeutics stock price, and Galectin Therapeutics historical stock prices before investing. While share price is an important factor, one should also look at financials and valuation metrics like the Galectin Therapeutics PE ratio chart. Below is a brief explanation of common balance sheet terms:

  • Assets: An asset is a resource that a corporation like Galectin Therapeutics owns and has economic value. The two major types of assets are: fixed assets like real estate, plant and machinery and current assets like cash, marketable securities and inventory. The total asset value for GALT stock as of 2018 Q2 is $11.21M. Its easy to associate the term with manufacturing companies, which invest a lot in factories and equipment. However, the same cannot be said about tech stocks.
  • Liabilities or obligations comprise of current liabilities that include short term loans, amounts payable to suppliers, or any other outstanding payments including long term liabilities that take into account long term loans for funding large projects. The total liabilities for Galectin Therapeutics is $1.44M. Shareholders equity comes under liabilities as it is money the company owes the holders of GALT stock.

Galectin Therapeutics Balance Sheet - Key Ratios